AARD
HEALTHCAREAardvark Therapeutics, Inc. Common Stock
AI Insight
What's Moving AARD Today?
No stock-specific AI insight has been generated for AARD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.35$17.94
$4.25
Fundamentals
Market Cap$86M
P/E Ratio—
EPS$-3.21
Dividend Yield—
Dividend / Share—
ROE-58.8%
Profit Margin—
Debt / Equity—
Trading
Volume36K
Avg Volume (10D)—
Shares Outstanding21.8M
AARD News
22 articles- Several Insiders Invested In Aardvark Therapeutics Flagging Positive NewsYahoo Finance·May 28, 2026
- FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4TipRanks·May 18, 2026
- Sector Update: Healthcare Stocks Decline Late AfternoonYahoo Finance·May 15, 2026
- Top Midday DeclinersYahoo Finance·May 15, 2026
- FDA hold puts Aardvark Prader-Willi drug in limboBiopharmadive·May 15, 2026
- Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical HoldThe Manila Times·May 15, 2026
- Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesYahoo Finance·May 7, 2026
- Discover 3 Promising Penny Stocks With Market Caps Over $100MYahoo Finance·Apr 17, 2026
- Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens BermanGlobeNewswire Inc.·Apr 9, 2026
- Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac FindingsYahoo Finance·Mar 29, 2026
- Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 23, 2026
- A Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO TrialYahoo Finance·Mar 5, 2026
- Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety QuestionsYahoo Finance·Mar 4, 2026
- Why Aardvark Therapeutics Just Lost More Than Half Its ValueYahoo Finance·Mar 2, 2026
- Sector Update: Health Care Stocks Retreat Late AfternoonYahoo Finance·Mar 2, 2026
- Safety concerns spur Aardvark to halt key Prader-Willi drug trialBiopharmadive·Mar 2, 2026
- Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi SyndromeYahoo Finance·Feb 27, 2026
- Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Feb 13, 2026
- Aardvark Therapeutics Announces Leadership AppointmentsYahoo Finance·Feb 12, 2026
- Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive OfficerYahoo Finance·Feb 12, 2026
- Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi SyndromeYahoo Finance·Feb 10, 2026
- Aardvark Therapeutics, Inc. (NASDAQ:AARD) stock most popular amongst retail investors who own 32%, while private equity firms hold 28%Yahoo Finance·Jan 19, 2026
All 22 articles loaded
Price Data
Open$4.06
Previous Close$4.08
Day High$4.31
Day Low$4.03
52 Week High$17.94
52 Week Low$3.35
52-Week Range
$3.35$17.94
$4.25
Fundamentals
Market Cap$86M
P/E Ratio—
EPS$-3.21
Dividend Yield—
Dividend / Share—
ROE-58.8%
Profit Margin—
Debt / Equity—
Trading
Volume36K
Avg Volume (10D)—
Shares Outstanding21.8M
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—